Prognostic significance of the postoperative level and recovery rate of serum albumin in patients with curatively resected pancreatic ductal adenocarcinoma

  • Authors:
    • Yutaka Nakano
    • Minoru Kitago
    • Masahiro Shinoda
    • Hiroshi Yagi
    • Yuta Abe
    • Kiminori Takano
    • Go Oshima
    • Ayano Takeuch
    • Yutaka Endo
    • Yuko Kitagawa
  • View Affiliations

  • Published online on: June 19, 2019     https://doi.org/10.3892/mco.2019.1883
  • Pages: 270-278
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the clinicopathological features and prognostic factors associated with pre‑ and postoperative serum albumin levels in patients with curatively resected pancreatic ductal adenocarcinoma (PDAC). To achieve this, the data of patients who underwent pancreatectomy for PDAC between January 1995 and March 2016 were retrospectively reviewed, and the pre‑ and postoperative serum albumin levels at postoperative months (POMs) 3, 6, and 12 were evaluated. The serum albumin recovery rate was also investigated. A total of 196 patients were enrolled in the present study. In the multivariate Cox regression analysis, lymph node metastasis [hazard ratio (HR): 1.65; P=0.022], serum albumin level at POM 12 (≥3.9 g/dl; HR: 0.60; P=0.017), and serum albumin recovery rate at POM 12 (≥1.00; HR: 0.60; P=0.017) were independent prognostic factors for disease‑free survival. Lymph node metastasis (HR: 1.79; P=0.013) and serum albumin level at POM 12 (≥3.9 g/dl) (HR: 0.60; P=0.033) were independent prognostic factors for overall survival. These results indicated that the postoperative level and recovery rate of serum albumin are potential biomarkers for predicting the prognosis of patients with curatively resected PDAC. However, further studies are required in order to investigate the survival benefit of increasing postoperative serum albumin levels in these patients.

References

1 

Egawa S, Toma H, Ohigashi H, Okusaka T, Nakano A, Hatori T, Maguchi H, Yanagisawa A and Tanaka M: Japan pancreatic cancer registry; 30th year anniversary: Japan pancreas society. Pancreas. 41:985–992. 2012. View Article : Google Scholar : PubMed/NCBI

2 

Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI

3 

Verma V, Li J and Lin C: Neoadjuvant therapy for pancreatic cancer: Systematic review of postoperative morbidity, mortality, and complications. Am J Clin Oncol. 39:302–313. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, et al: Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: A phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 388:248–257. 2016. View Article : Google Scholar : PubMed/NCBI

5 

Farrugia A: Albumin usage in clinical medicine: Tradition or therapeutic? Transfus Med Rev. 24:53–63. 2010. View Article : Google Scholar : PubMed/NCBI

6 

Gabay C and Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Eng J Med. 340:448–454. 1999. View Article : Google Scholar

7 

Namendys-Silva SA, Gonzalez-Herrera MO, Texcocano-Becerra J and Herrera-Gomez A: Hypoalbuminemia in critically ill patients with cancer: Incidence and mortality. Am J Hosp Palliat Care. 28:253–257. 2011. View Article : Google Scholar : PubMed/NCBI

8 

Fuhrman MP: The albumin-nutrition connection: Separating myth from fact. Nutrition. 18:199–200. 2002. View Article : Google Scholar : PubMed/NCBI

9 

Visser M, Kritchevsky SB, Newman AB, Goodpaster BH, Tylavsky FA, Nevitt MC and Harris TB: Lower serum albumin concentration and change in muscle mass: The health, aging and body composition study. Am J Clin Nutr. 82:531–537. 2005. View Article : Google Scholar : PubMed/NCBI

10 

Haruki K, Shiba H, Shirai Y, Horiuchi T, Iwase R, Fujiwara Y, Furukawa K, Misawa T and Yanaga K: The C-reactive protein to albumin ratio predicts long-term outcomes in patients with pancreatic cancer after pancreatic resection. World J Surg. 40:2254–2260. 2016. View Article : Google Scholar : PubMed/NCBI

11 

Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S and Nakao A: Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 98:268–274. 2011. View Article : Google Scholar : PubMed/NCBI

12 

Imaoka H, Mizuno N, Hara K, Hijioka M, Tajika M, Tanaka T, Ishihara M, Yogi T, Tsutsumi H, Fujiyoshi T, et al: Evaluation of modified glasgow prognostic score for pancreatic cancer: A retrospective cohort study. Pancreas. 45:211–217. 2016. View Article : Google Scholar : PubMed/NCBI

13 

Nakano Y, Kitago M, Matsuda S, Nakamura Y, Fujita Y, Imai S, Shinoda M, Yagi H, Abe Y, Hibi T, et al: KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: A retrospective study. Br J Cancer. 118:662–669. 2018. View Article : Google Scholar : PubMed/NCBI

14 

Nakano Y, Kitago M, Shinoda M, Abe Y, Yagi H, Hibi T, Takeuchi A, Aiura K, Itano O and Kitagawa Y: Clinical predictive factors of long-term survival after curative resection of pancreatic cancer: A retrospective study. Br J Cancer. 6:2278–2281. 2018.

15 

Fujii-Nishimura Y, Nishiyama R, Kitago M, Masugi Y, Ueno A, Aiura K, Kawachi S, Kawaida M, Abe Y, Shinoda M, et al: Two cases of pathological complete response to neoadjuvant chemoradiation therapy in pancreatic cancer. Keio J Med. 64:26–31. 2015. View Article : Google Scholar : PubMed/NCBI

16 

Japan Pancreas Society: Classification of pancreatic carcinoma. 2nd English ed. Tokyo. Kanehara2009.

17 

Takahashi S, Aiura K, Saitoh J, Hayatsu S, Kitajima M and Ogata Y: Treatment strategy for pancreatic head cancer: Pylorus-preserving pancreatoduodenectomy, intraoperative radiotherapy and portal catheterization. Digestion. 60 (Suppl):S130–S134. 1999. View Article : Google Scholar

18 

Aiura K, Takahashi S, Matsui J, Ueda M and Kitagawa Y: Beneficial effects of 5-Fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin C and cisplatin after curative resection of pancreatic cancer. Pancreatology. 10:250–258. 2017. View Article : Google Scholar

19 

McMillan DC, Watson WS, O'Gorman P, Tom Preston, Scott HR and McArdle CS: Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 39:210–213. 2001. View Article : Google Scholar : PubMed/NCBI

20 

Schmid I, Schmitt M, Streiter M, Meilbeck R, Haas RJ and Stachel DK: Effects of soluble TNF receptor II (sTNF-RII), IL-1 receptor antagonist (IL-1ra), tumor load and hypermetabolism on malnutrition in children with acute leukemia. Eur J Med Res. 10:457–461. 2005.PubMed/NCBI

21 

Matsuda S, Niihara M, Tsubosa Y, Sato H, Takebayashi K, Kawamorita K, Mori K, Tsushima T, Yasui H, Takeuchi H and Kitagawa Y: Clinical significance of postoperative recovery of serum albumin levels in patients with esophageal cancer who underwent transthoracic esophagectomy. Surg Today. 46:1138–1145. 2016. View Article : Google Scholar : PubMed/NCBI

22 

Ravasco P, Monteiro-Grillo I, Vidal PM and Camilo ME: Dietary counseling improves patient outcomes: A prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol. 23:1431–1438. 2005. View Article : Google Scholar : PubMed/NCBI

23 

Roxburgh CSD, Crozier JEM, Maxwell F, Foulis AK, Brown J, McKee RF, Anderson JH, Horgan PG and McMillan DC: Comparison of tumour based (Petersen Index) and inflammation-based (Glasgow Prognostic Score) scoring systems in patients undergoing curative resection for colon cancer. Br J Cancer. 100:701–706. 2009. View Article : Google Scholar : PubMed/NCBI

24 

McMillan DC, Crozier JE, Canna K, Angerson WJ and McArdle CS: Evaluation of an inflammation based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 22:881–886. 2007. View Article : Google Scholar : PubMed/NCBI

25 

Gilliland TM, Villafane-Ferriol N, Shah KP, Shah RM, Tran Cao HS, Massarweh NN, Silberfein EJ, Choi EA, Hsu C and McElhany CA: Nutritional and metabolic derangements in pancreatic cancer and pancreatic resection. Nutrients. 9:E2432017. View Article : Google Scholar : PubMed/NCBI

26 

Shu XL, Kang K, Gu LJ and Zhang YS: Effect of early enteral nutrition on patients with digestive tract surgery: A meta-analysis of randomized controlled trials. Exp Ther Med. 12:2136–2144. 2016. View Article : Google Scholar : PubMed/NCBI

27 

Okada S, Yamazaki S, Kaiga T, Funada T, Kochi M and Takayama T: Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy. World J Surg Oncol. 15:162–169. 2017. View Article : Google Scholar : PubMed/NCBI

28 

Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Chone L, Francois E, Artru A, Biagi JJ, et al: Folfirinox or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 379:2395–2406. 2018. View Article : Google Scholar : PubMed/NCBI

29 

Fleck A, Raines G, Hawker F, Trotter J, Wallace PI, Ledingham IM and Calman KC: Increased vascular permeability: A major cause of hypoalbuminaemia in disease and injury. Lancet. 1:781–784. 1985. View Article : Google Scholar : PubMed/NCBI

30 

Hubner M, Mantziari S, Demartines N, Pralong F, Coti-Bertrand P and Schafer M: Postoperative albumin drop is a marker for surgical stress and a predictor for clinical outcome: A pilot study. Gastroenterol Res Pract. 87431872016.PubMed/NCBI

31 

Gao Q, Mok HP, Wang WP, Xiao F and Chen LQ: Effect of perioperative glucocorticoid administration on postoperative complications following esophagectomy: A meta-analysis. Oncol Lett. 7:349–356. 2014. View Article : Google Scholar : PubMed/NCBI

32 

Takata A, Takiguchi S, Miyazaki Y, Miyata H, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Mori M, Kanagawa K and Doki Y: Randomized phase II study of the anti-inflammatory effect of ghrelin during the postoperative period of esophagectomy. Ann Surg. 262:230–236. 2015. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2019
Volume 11 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Nakano, Y., Kitago, M., Shinoda, M., Yagi, H., Abe, Y., Takano, K. ... Kitagawa, Y. (2019). Prognostic significance of the postoperative level and recovery rate of serum albumin in patients with curatively resected pancreatic ductal adenocarcinoma. Molecular and Clinical Oncology, 11, 270-278. https://doi.org/10.3892/mco.2019.1883
MLA
Nakano, Y., Kitago, M., Shinoda, M., Yagi, H., Abe, Y., Takano, K., Oshima, G., Takeuch, A., Endo, Y., Kitagawa, Y."Prognostic significance of the postoperative level and recovery rate of serum albumin in patients with curatively resected pancreatic ductal adenocarcinoma". Molecular and Clinical Oncology 11.3 (2019): 270-278.
Chicago
Nakano, Y., Kitago, M., Shinoda, M., Yagi, H., Abe, Y., Takano, K., Oshima, G., Takeuch, A., Endo, Y., Kitagawa, Y."Prognostic significance of the postoperative level and recovery rate of serum albumin in patients with curatively resected pancreatic ductal adenocarcinoma". Molecular and Clinical Oncology 11, no. 3 (2019): 270-278. https://doi.org/10.3892/mco.2019.1883